Company profile
Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| KER-047 | phase2 | — | 1 | withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05927012 | phase2 | withdrawn | 2023-11-30 | 2025-08-29 | Keros Therapeutics, Inc. | A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). |
| NCT05975905 | phase2 | terminated | 2023-10-17 | 2025-03-05 | Keros Therapeutics, Inc. | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). |
| NCT07704099 | phase2 | not_yet_recruiting | 2026-09-14 | 2029-07-17 | Keros Therapeutics, Inc. | Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy |
FDA applications (0)
No records yet.